Cancer Genetics to Participate in Upcoming Investor Conferences

RUTHERFORD, N.J., Nov. 30, 2017 -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that the executive management of the company is scheduled to participate in two upcoming investor conferences:

• 10^th Annual LD Micro Main Event
  Presentation: Tuesday, December 5^th at 9:00 a.m. PST / 12:00 p.m. EST
  Location: Track 3 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA
  

• Benchmark Micro Cap Discovery One-on-One Conference
  The Company will participate in one-on-one meetings throughout the conference being held at the Palmer House Hilton on December 14^th in Chicago, IL.

Investors attending these conferences who would like to schedule a one-on-one meeting with Cancer Genetics management may do so by contacting their LD Micro or Benchmark representative, or Lee Roth or Robert Flamm at The Ruth Group at [email protected] / [email protected].

ABOUT CANCER GENETICS
Cancer Genetics Inc. (CGI) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI has developed a global footprint with locations in the US, India and China. The Company has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.

The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2016 and the Form 10-Q for the Quarter ended September 30, 2017 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.

Contacts
Media Relations
Kirsten Thomas
508-280-6592
[email protected]

Investor Relations
Lee Roth / Robert Flamm
646-536-7012 / 7017
[email protected] / [email protected]